Further observations on the inhibition of tumor growth byC. parvum with cyclophosphamide.VII. Effect of treatment prior to primary tumor removal on the growth of distant tumor

Fisher, Bernard; Gebhardt, Mark C.; Saffer, Elizabeth

doi:10.1002/1097-0142(197902)43:2<451::aid-cncr2820430208>3.0.co;2-h

Cited by 34 publications

(38 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Note that the intratumoral immunotherapy alone had no anti-tumour eOE ect. In other early papers from the group directed by Fisher et al (1979) at the University of Pittsburgh, combined preoperative intratumoral chemo-immunotherapy was also found to be eOE ective using cyclophosphamide chemotherapy with Corynebacterium parvum immunotherapy in a spontaneous mammary carcinoma from C3H}HeJ mice. In this case, chemotherapy alone did not appear to be bene® cial.…”

Section: Immune Response Due To Intratumoral Chemotherapy and Chemo-isupporting

confidence: 86%

Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery

Goldberg

Hadba

Almond

et al. 2002

Journal of Pharmacy and Pharmacology

177

143

View full text Add to dashboard Cite

The recent literature documents the growing interest in local intratumoral chemotherapy as well as systemic preoperative chemotherapy with evidence for improved outcomes using these therapeutic modalities. Nevertheless, with few exceptions, the conventional wisdom and standard of care for clinical and surgical oncology remains surgery followed by radiation and/or systemic chemotherapy, as deemed appropriate based on clinical ndings. This, in spite of the fact that the toxicity of conventional systemic chemotherapy and immunotherapy affords limited effectiveness and frequently compromises the quality of life for patients. Indeed, with systemic chemotherapy, the oncologist (and the patient) often walks a ne line between attempting tumour remission with prolonged survival and damaging the patient's vital functions to the point of death. In this context, it has probably been obvious for more than 100 years, due in part to the pioneering work of Ehrlich (1878), that targeted or localized drug delivery should be a major goal of chemotherapy. However, there is still only limited clinical use of nonsystemic intratumoral chemotherapy for even those high mortality cancers which are characterized by well de ned primary lesions i.e. breast, colorectal, lung, prostate, and skin.There has been a proliferation of intratumoral chemotherapy and immunotherapy research during the past two to three years. It is therefore the objective of this review to focus much more attention upon intratumoral therapeutic concepts which could limit adverse systemic events and which might combine clinically feasible methods for localized preoperative chemotherapy and/or immunotherapy with surgery. Since our review of intratumoral chemo- Given the state-of-the-art in clinical and surgical oncology, and the advances that have been made in intratumoral drug delivery, minimally invasive tumour access i.e. ne needle biopsy, new drugs and drug delivery systems, and preoperative chemotherapy, it is timely to present a review of studies which may suggest future opportunities for safer, more effective, and clinically practical non-systemic therapy. General perspective for traditional systemic therapiesThe toxicity of conventional systemic cancer chemotherapy and immunotherapy has severely limited the safety and eOE ectiveness of such therapy. The quality of life

show abstract

Section: Immune Response Due To Intratumoral Chemotherapy and Chemo-isupporting

confidence: 86%

Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery

Goldberg

Hadba

Almond

et al. 2002

Journal of Pharmacy and Pharmacology

177

143

View full text Add to dashboard Cite

show abstract

“…For example, under the balance of small antitumor immunity against a large tumor burden, the immunity will likely become exhausted simply because of the overwhelming antigen load [ 107 ]. In such situations, surgery can help to significantly tilt the balance toward better disease control due to the pre-surgery concomitant antitumor immunity that needs to be activated [ 108 – 110 ]; otherwise, the antitumor immunity will likely contract with antigen reduction and the patient will lose protection against recurrence and metastases [ 64 ]. This explains some of the cases where known incomplete surgery still resulted in disease-free survival.…”

Section: Immunological Views Of Cancer Surgerymentioning

confidence: 99%

Tumor reductive therapies and antitumor immunity

Tsung

2017

Oncotarget

View full text Add to dashboard Cite

Tumor reductive therapy is to reduce tumor burden through direct killing of tumor cells. So far, there is no report on the connection between antitumor immunity and tumor reductive therapies. In the last few years, a new category of cancer treatment, immunotherapy, emerged and they are categorized separately from classic cytotoxic treatments (chemo and radiation therapy). The most prominent examples include cellular therapies (LAK and CAR-T) and immune checkpoint inhibitors (anti-PD-1 and CTLA-4). Recent advances in clinical immunotherapy and our understanding of the mechanism behind them revealed that these therapies have a closer relationship with classic cancer treatments than we thought. In many cases, the effectiveness of classic therapies is heavily influenced by the status of the underlying antitumor-immunity. On the other hand, immunotherapies have shown better outcome when combined with tumor reductive therapies, not only due to the combined effects of tumor killing by each therapy but also because of a synergy between the two. Many clinical observations can be explained once we start to look at these classic therapies from an immunity standpoint. We have seen their direct effect on tumor antigen in vivo that they impact antitumor immunity more than we have realized. In turn, antitumor immunity contributes to tumor control and destruction as well. This review will take the immunological view of the classic therapies and summarize historical as well as recent findings in animal and clinical studies to make the argument that most of the cancer treatments exert their ultimate efficacy through antitumor immunity.

show abstract

“…Existía información que sugería que la extirpación del tumor primario podría aumentar el índice de crecimiento de las micrometástasis existentes. En contraste, estudios en modelos animales sugerían que el tratamiento neoadyuvante podría eliminar este riesgo (18)(19)(20) . Estos datos condujeron al desarrollo de ensayos clínicos que comparaban la quimioterapia prequirúrgica versus la poscirugía (12,13,(21)(22)(23)(24)(25)(26)(27)(28) .…”

Section: La Quimioterapia Neoadyuvanteunclassified

La quimioterapia neoadyuvante en el tratamiento del cáncer de mama localmente avanzado

Zaharia¹,

Gómez

2014

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

Al inicio del tratamiento del cáncer, se pensaba que este se diseminaba por continuidad, lo cual originó que las primeras estrategias para el manejo de cáncer de mama localmente avanzado fueran altamente agresivas, además de mutilantes. Con los avances en el conocimiento de la biología de la enfermedad, se generaron importantes cambios en el manejo de esta neoplasia. Surgió entonces como alternativa terapéutica la quimioterapia neoadyuvante, que es aquella que se administra previamente al tratamiento quirúrgico. Descrita inicialmente por la escuela de Milán, ha probado ser una mejor alternativa que el tratamiento quirúrgico solo, que la quimioterapia adyuvante (o postquirúrgica) y que la radioterapia sola o en combinación con las técnicas señaladas previamente. Dentro de las ventajas de la quimioterapia neoadyuvante se encuentran el incremento de la tasa de las cirugías conservadoras de mama y la disminución de la tasa de recaída ipsilateral. Facilita además el control y seguimiento de la enfermedad. Sin embargo, la principal desventaja es que no puede modificar algunos factores pronósticos de la enfermedad como la relación tumor mama, enfermedad multicéntrica, las microcalcificaciones dispersas y la coexistencia de procesos médicos que contraindiquen la radioterapia. Actualmente, la quimioterapia neoadyuvante es la base del manejo del cáncer de mama localmente avanzado y está recomendada para garantizar una evolución más conservadora en el manejo de esta enfermedad.

show abstract

Further observations on the inhibition of tumor growth byC. parvum with cyclophosphamide.VII. Effect of treatment prior to primary tumor removal on the growth of distant tumor

Cited by 34 publications

References 20 publications

Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery

Intratumoral cancer chemotherapy and immunotherapy: opportunities for nonsystemic preoperative drug delivery

Tumor reductive therapies and antitumor immunity

La quimioterapia neoadyuvante en el tratamiento del cáncer de mama localmente avanzado

Contact Info

Product

Resources

About